ACAD
27.65
+0.6
+2.22%
AEMD
4.96
+0.03
+0.61%
APRI
0.459
-0.011
-2.3617%
ARNA
1.56
-0.02
-0.95%
ATEC
0.214
-0.012
-5.1111%
CNAT
2.34
-0.21
-8.24%
CRXM
0.188
-0.001
-0.476%
CYTX
0.25
+0.01
+5.57%
DXCM
61.31
-0.09
-0.15%
GNMK
5.42
-0.06
-1.09%
HALO
9.5
-0.13
-1.35%
ILMN
140.71
+1.81
+1.30%
INNV
0.089
+0.019
+27.143%
INO
8.96
-0.12
-1.32%
ISCO
3.6
-0.09
-2.44%
ISIS
57.56
0.00
0.00%
LGND
119.17
+0.93
+0.79%
LPTN
0.225
-0.001
-0.2222%
MBVX
0.65
0.00
0.00%
MEIP
1.34
-0.03
-2.19%
MNOV
6.91
+0.23
+3.44%
MRTX
15.9
-3
-15.87%
MSTX
0.317
-0.002
-0.627%
NBIX
42.87
+0.22
+0.52%
NUVA
52.64
+0.04
+0.08%
ONCS
1.6
-0.07
-4.19%
ONVO
2.62
0.00
0.00%
OREX
0.376
-0.035
-8.4105%
OTIC
12.14
-0.54
-4.26%
QDEL
16.23
+0.14
+0.87%
RCPT
231.96
0.00
0.00%
RGLS
5.38
+0.02
+0.37%
RMD
56.48
+0.07
+0.12%
SPHS
1.57
+0.24
+18.05%
SRNE
5.8
-0.74
-11.31%
TROV
3.57
-0.01
-0.28%
VICL
0.368
-0.012
-3.2640%
VOLC
18
0.00
0.00%
ZGNX
9.45
-0.03
-0.32%
ACAD
27.65
+0.6
+2.22%
AEMD
4.96
+0.03
+0.61%
APRI
0.459
-0.011
-2.3617%
ARNA
1.56
-0.02
-0.95%
ATEC
0.214
-0.012
-5.1111%
CNAT
2.34
-0.21
-8.24%
CRXM
0.188
-0.001
-0.476%
CYTX
0.25
+0.01
+5.57%
DXCM
61.31
-0.09
-0.15%
GNMK
5.42
-0.06
-1.09%
HALO
9.5
-0.13
-1.35%
ILMN
140.71
+1.81
+1.30%
INNV
0.089
+0.019
+27.143%
INO
8.96
-0.12
-1.32%
ISCO
3.6
-0.09
-2.44%
ISIS
57.56
0.00
0.00%
LGND
119.17
+0.93
+0.79%
LPTN
0.225
-0.001
-0.2222%
MBVX
0.65
0.00
0.00%
MEIP
1.34
-0.03
-2.19%
MNOV
6.91
+0.23
+3.44%
MRTX
15.9
-3
-15.87%
MSTX
0.317
-0.002
-0.627%
NBIX
42.87
+0.22
+0.52%
NUVA
52.64
+0.04
+0.08%
ONCS
1.6
-0.07
-4.19%
ONVO
2.62
0.00
0.00%
OREX
0.376
-0.035
-8.4105%
OTIC
12.14
-0.54
-4.26%
QDEL
16.23
+0.14
+0.87%
RCPT
231.96
0.00
0.00%
RGLS
5.38
+0.02
+0.37%
RMD
56.48
+0.07
+0.12%
SPHS
1.57
+0.24
+18.05%
SRNE
5.8
-0.74
-11.31%
TROV
3.57
-0.01
-0.28%
VICL
0.368
-0.012
-3.2640%
VOLC
18
0.00
0.00%
ZGNX
9.45
-0.03
-0.32%
Home » Archive by Category

Syndication

Chemist/Assistant Chemist (San Diego)

April 18, 2016 – 6:09 pm

Positions: Chemist and Assistant Chemist
Industry: Biotech
Location: Mira Mesa
Qualifications:
-BS or BA Biochem or Chemistry preferably with 0-1 years exp.
-Knowledgable in organic chemistry, HPLC and purification methods.
-Motivated individua […

Senior Manufacturing Automation Engineer – Real Staffing – San Diego, CA

April 18, 2016 – 2:57 pm

Automation Engineer, Automation, Manufacturing Engineer, Manufacturing, Senior, Optimization, Automation Systems, Medical Devices, Biotech, Biotechnology….$45 – $60 an hour
From Real Staffing – 18 Apr 2016 21:57:53 GMT
– View…

Scientist II, ADME – BioPhase Solutions – San Diego, CA

April 18, 2016 – 2:39 pm

We are currently looking for a QC Microbiology Analyst to work for a leading San Diego biotechnology company….
From BioPhase Solutions – 18 Apr 2016 21:39:15 GMT
– View all San Diego jobs

Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment

April 18, 2016 – 1:01 pm

Adenosine Targeting Immune-Checkpoint Inhibitor and Anti-EGFR Antibody-Drug Conjugate Demonstrate Tumor Growth Inhibition in Pre-Clinical Studies

SAN DIEGO, April 18, 2016 /PRNewswire/ — Halozyme Therapeutics (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced preclinical data for the discovery and early development of two potential drug candidates, an immune checkpoint inhibitor targeting adenosine and a novel antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR). 

These new preclinical programs complement Halozyme’s lead oncology asset, PEGPH20, an investigational new drug (IND) under clinical evaluation for the treatment of pancreatic, lung and gastric cancers.

The potential drug candidates are PEGylated adenosine deaminase 2, or PEG-ADA2, an immune checkpoint inhibitor that targets immuno-suppressive adenosine, which may accumulate to high levels in the tumor microenvironment. PEG-ADA2 is currently in early preclinical development with the next milestone expected to be final drug candidate selection by the end of 2016.

HTI-1511 is a novel anti-EGFR ADC to treat solid tumors, including those with drug-resistant mutations. It is also in pre-clinical development, with a drug candidate selected, good laboratory practices (GLP) toxicity studies planned for 2017 and chemistry, manufacturing and controls (CMC) development activities to support a future IND filing underway.

“We expand our oncology pipeline today with two assets that complement our growing body of research into the structural, biochemical and immunological properties of the tumor microenvironment,” said Dr. Helen Torley, president and chief executive officer. “Our new PEG-ADA2 and HTI-1511 anti-EGFR ADC show early promise as our scientists continue to characterize them for potential clinical study in the future.

“In addition, our ongoing research of lead asset, PEGPH20, continues to build scientific evidence of potential benefits in remodeling the tumor microenvironment, including the potential to increase access of immune therapies and chemotherapies. This week we will share new research in animal models showing increased tumor regression when immune checkpoint inhibitors are used in combination with PEGPH20 in tumor models with high levels of hyaluronan.”

The new studies are being introduced during poster presentations at the American Association for Cancer Research (AACR) annual conference, taking place April 17-20 in New Orleans.

PEG-ADA2

Halozyme’s PEG-ADA2 was engineered to decrease the concentration of adenosine in the tumor microenvironment, and PEGylated to prolong its circulation in the body. Accumulation of adenosine is believed to contribute to a suppressed immune response to certain solid tumors.

In preclinical studies, Halozyme’s PEG-ADA2 demonstrated tumor growth inhibition in certain colon, lung and pancreatic cancer models. Treatment with PEG-ADA2 resulted in an increase in infiltration of T cells and lowering of tumor adenosine levels. Halozyme scientists have also identified a potential biomarker for tumors that may respond to PEG-ADA2 therapy.

The company plans to continue its ongoing study and characterization of PEG-ADA2 with the goal of determining its suitability as a targeted therapy for clinical study.

HTI-1511 Anti-EGFR ADC

Halozyme’s HTI-1511 was engineered to bind to EGFR at the low pH of the tumor microenvironment while decreasing or attenuating the binding at the neutral pH of skin. The result in preclinical studies to date is a targeted therapy with an acceptable safety profile.

HTI-1511 has been developed as a next generation ADC with a potent cytotoxin, monomethyl auristatin E to treat EGFR-positive tumors, including those with KRAS and BRAF mutations. In preclinical studies, HTI-1511 has demonstrated tumor growth inhibition or regression in colon, lung and cholangiocarcinoma models, including patient derived xenograft (PDx) models with known KRAS and BRAF mutations.

The company has initiated a range of studies to prepare for an IND filing for HTI-1511 with the target of initiating early clinical study in 2018.

Halozyme Webcast and Conference Call

Dr. Torley and Halozyme Chief Scientific Officer, Dr. Michael LaBarre will host a meeting for investment professionals today, Monday, April 18 at 4 p.m. ET (3 p.m. CT, 1 p.m. PT). The event will be webcast live through the “Investors” section of Halozyme’s corporate website and a recording will be made available following the close of the event.

To access the webcast and additional documents related to the event, please visit www.halozyme.com approximately fifteen minutes prior to the start time to register, download and install any necessary audio software. The live event may be accessed by calling (877) 410-5657 (domestic callers) or (334) 323-7224 (international callers) using passcode 987221. A telephone replay will be available after the event by dialing (877) 919-4059 (domestic callers) or (334) 323-0140 (international callers) using replay passcode 13259083.

Halozyme’s AACR Poster Presentations include:

  1. PEGylated recombinant hyaluronidase PH20 enhances pemetrexed antitumor efficacy in a human non-small cell lung cancer model, Sun., April 17, 1-5 p.m. CT
  2. Preclinical evaluation of a next-generation EGFR targeting antibody-drug conjugate that promotes regression in KRAS and BRAF tumors, Mon., April 18, 8 a.m.noon CT
  3. Enzymatic depletion of adenosine by PEGylated, engineered adenosine deaminase 2 (PEG-ADA2): a novel immunotherapeutic approach to treat solid tumors, Mon., April 18, 8 a.m.noon CT
  4. PEGPH20 increases the anticancer activity of standard chemotherapy combinations, vincristine (VIN) and D actinomycin (DACT), in a Wilms xenograft model, Mon., April 18, 1-5 p.m. CT
  5. PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances checkpoint inhibitor efficacy in syngeneic mouse models of cancer, Weds., April 20, 8 a.m.noon CT

About PEGPH20

PEGPH20 is an investigational PEGylated form of Halozyme’s proprietary recombinant human hyaluronidase under clinical development for the potential systemic treatment of tumors that accumulate hyaluronan. FDA granted orphan drug designation to PEGPH20 for treatment of pancreatic cancer and fast track for PEGPH20 in combination with gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer.

Additionally, the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency, designated investigational drug PEGPH20 an orphan medicinal product for the treatment of pancreatic cancer.

About Halozyme

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Safe Harbor Statement 

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the possible activity, benefits and attributes of PEGPH20, PEG-ADA2 and HTI-1511, their possible method of action, potential application to improve cancer therapies and statements concerning future actions and clinical trials relating to their development) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company’s Annual Report on Form 10-K recently filed with the Securities and Exchange Commission.

Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com

Chris Burton
858-704-8352
ir@halozyme.com

Logo – http://photos.prnewswire.com/prnh/20100302/LA63139LOGO

 

SOURCE Halozyme Therapeutics, Inc.

Biocom Establishes Los Angeles Office, Appoints Dina Lozofsky as Executive Director

April 18, 2016 – 12:36 pm

SAN DIEGO and LOS ANGELES, April 18, 2016 /PRNewswire/ — Biocom, the organization that has been driving the success of Southern California’s life science industry for more than 20 years, today announced the launch of its Los Angeles operations and the appointment of Dina Lozofsky as executive director of the new office.

Biocom’s goal in Los Angeles is to accelerate the growth of a thriving, dynamic life sciences community, leveraging the many building blocks already in place. Nearly 300 biopharmaceutical and medical device companies call Los Angeles County home, in addition to some of the nation’s finest teaching hospitals and biomedical research organizations. The area also boasts a highly skilled talent pool of life science graduates, many with advanced degrees.

Los Angeles as a region has enormous potential to unify and thrive as a successful life science cluster,” said Joe Panetta, President and CEO of Biocom.  “As we listen to the needs of the industry, we see activities and programs we can introduce, and best practices we can offer, to promote the success of L.A. as a life science powerhouse.  Our long-term goal is to bring a strong, cohesive voice that advocates for the industry, venture capital funding, regulatory pathways, partnerships, technology transfer, and talent retention.  We recognize a trend of entrepreneurs taking innovations they discovered in Los Angeles to companies in other parts of the country for further development and commercialization.  As an experienced industry organization, Biocom can help bring together the elements needed to create a thriving life science community in Los Angeles.”

In San Diego, Biocom has fostered one of the largest, most active life science clusters in the world. Biocom’s Los Angeles office will work closely with Biocom’s cadre of existing members in Los Angeles county, as well as other key industry stakeholders, to identify the unique needs and opportunities of the region.

Los Angeles has enormous potential to harness its strengths in life science to become a true powerhouse for innovation, on par with other leading life science clusters of the world,” said Ms. Lozofsky. “With the launch of Biocom’s Los Angeles office, work will begin immediately to set and act upon goals for the region.”        

Ms. Lozofsky brings more than two decades of experience in the science and technology industries of Southern California, where she has specialized in transferring ideas from academic institutions to entrepreneurs, and in commercializing those technologies once they are brought in house. Most recently, she served as associate director for licensing and business development at University of California, Santa Barbara’s Office of Technology and Industry Alliances, where she designed, launched and led a program to mentor and support startup companies formed around UCSB technology. She also has worked in the technology transfer offices of both University of California, Los Angeles and University of Southern California, and has served in various private sector roles including as vice president of corporate development for a next generation solar company, Solarmer Energy. Ms. Lozofsky is active on the board of the Los Angeles Venture Association and is a registered patent agent. She holds a B.S. in aerospace engineering from the Massachusetts Institute of Technology and an M.B.A. from USC’s Marshall School of Business.

About Biocom

Biocom is one of the largest regional life science associations in the world, representing 750 member companies in Southern California. The association focuses on initiatives that position the region’s life science industry competitively on the world stage, and on the development and delivery of innovative products that improve health and quality of life. For more information on Biocom’s new office to serve the life science community in the greater Los Angeles region, please visit: www.biocomla.org.

For more information on Biocom or the Southern California biotechnology and medical device community, please visit the organization’s Web site at www.biocom.org. Connect with us on Facebook, LinkedIn, Instagram and Twitter (@BIOCOMCA).

Biocom Media Contact:
Heidi Chokeir
Canale Communications
Heidi@canalecomm.com
(619) 849-5377

Logo – http://photos.prnewswire.com/prnh/20130228/LA69104LOGO

 

SOURCE Biocom

Weighing and Blending Associate (Oceanside)

April 18, 2016 – 11:49 am

We have multiple positions open – two (2) immediate needs for Weighing and Blending Associates with GMP and manufacturing experience!!! High School diploma, AS, or Biotech certificate with an excellent work ethic.
Weighing and Blending Associate, Oc […

ADI-PEG 20 is a Potential Salvage Therapy for BRAFi Resistant Melanoma

April 18, 2016 – 10:30 am

SAN DIEGO, April 18, 2016 /PRNewswire/ — Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, is a potential salvage therapy for BRAF inhibitor (BRAFi) resistant melanoma according to results generated by researchers from University of Miami, Taipei Medical University, and MD Anderson Cancer Center.  The results will be presented at the American Association for Cancer Research’s 2016 annual meeting in New Orleans, Louisiana.

In xenograft models of melanoma, ADI-PEG 20 treatment stopped tumor growth of BRAFi-resistant (BR) cells, while slowing tumor growth of the parental cells (BRAFi sensitive).  Five BR melanoma cell lines derived from cells with known BRAF mutations were found to have very low levels of argininosuccinate synthetase (ASS1), the rate limiting enzyme in the arginine synthesis pathway in cells, and attenuated expression of AMPK-α 1, which governs autophagy and glucose uptake by cells.  ASS1 deficiency caused the BR cells to rely exclusively on external supply of arginine, while low AMPK-α 1 led to attenuation of glucose uptake, increased reliance on amino acids, and impaired ability to handle nutritional stress.  The dual deficiency of ASS1 and AMPK-α 1 renders the BR cells to be hypersensitive to treatment by ADI-PEG 20, which degrades arginine to citrulline.  Immunohistochemistry staining confirmed low levels of ASS1 and AMPK-α 1 in xenograft tumor tissues and the tumor tissues from 10 BR patients.  These findings also apply to tumor samples from patients who failed BRAF and MEK inhibitors, making ADI-PEG 20 a potential salvage therapy for BR patients.

Polaris Group is conducting clinical trials on ADI-PEG 20 for the treatment of multiple indications, including metastatic melanoma, malignant plural mesothelioma, and hepatocellular carcinoma.

“Although BRAFi and MEK inhibitor combination is highly effective in treating patients harboring BRAF V600E mutations, eventually tumors become resistant to BRAFi and these patients then relapse.  We are excited about the discovery that ADI-PEG 20 can potentially become a treatment option for these patients,” said John Bomalaski, M.D., Executive Vice President of Medical Affairs at Polaris Pharmaceuticals, Inc.

About ADI-PEG 20

ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient’s normal cells unharmed.  Multiple cancers have been reported to have a high degree of arginine-dependency.

About Polaris Group

Polaris Group, a multinational biopharmaceutical drug company, specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. Polaris Group is investigating ADI-PEG 20 as a treatment for a number of cancers, such as leukemia, lymphoma, melanoma, mesothelioma, non-small cell lung cancers, sarcoma, breast, ovarian, pancreatic cancer and hepatocellular carcinoma. In addition to the ADI-PEG 20 program, Polaris Group is researching and developing other biotherapeutic agents and is advancing a small molecule drug program that utilizes a rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.com.

Logo – http://photos.prnewswire.com/prnh/20141117/159166LOGO

 

SOURCE Polaris Group

Agenda Posted For Napa Summit: Request Invite to Star-Studded Event

April 18, 2016 – 10:29 am

It’s four weeks until Napa Summit 2016: The Xconomy Retreat on the Economy, Jobs, and Growth. We have now posted the agenda, and we’d love to see you there. So request your invitation today to…

[[Click headline to continue reading.]]

Clinical Lab Scientist (Oceanside)

April 18, 2016 – 9:58 am

Tri-City Medical Center is looking for a Clinical Lab Scientist to join our team!
Per Diem, Eve Shift
To Apply: https://careers-tricitymed.icims.com/jobs/3859/clinical-lab-scientist/job
Position Summary:
Performs clinical laboratory test procedur […

Real Estate Internet Marketing Sales Consultant – $45,000-$85,000year (San Diego)

April 18, 2016 – 9:22 am

15-year-old Digital Marketing company seeking to hired new inside sales consultants. The company provides Social Media, Web Marketing, SEO and other online marketing solutions to real estatre professionals throughout the USA.
We especially are seekin […